1.This is used to detect the status of ALK gene rearrangement in human non-small cell lung cancer.
2.Studies have shown that the proportion of ALK-positive cases can reach over 30% in patients with non-small cell lung cancer.
3.FISH detection of ALK-positive non-small cell lung cancer can assist in treatment with XALKORI (crizotinib).
4.Pathomorphological studies indicate that the positivity rate is higher in mucinous or solid adenocarcinomas containing signet-ring cells than in other types of lung cancer.